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Background: The purpose of the study was to evaluate the feasibility of deformable image registration (DIR) in
assessing cumulative dose distributions of the combination of external beam radiotherapy (EBRT) and fractionated
intracavitary brachytherapy (ICBT) for cervical cancer.
Materials and methods: Three-dimensional image data sets of five consecutive patients were used. The treatment
plan consisted of whole pelvic EBRT (total dose: 45 Gy in 25 fractions) combined with computed tomography
(CT)-based high-dose rate ICBT (≥24 Gy in 4 fractions to the high risk clinical target volume (HR-CTV)). Organs at risk and
HR-CTV were contoured on each CT images and dose-volume parameters were acquired. Pre-imaging preparations were
performed prior to each ICBT to minimize the uncertainty of the organ position. Physical doses of each treatment were
converted to biologically equivalent doses in 2 Gy daily fractions by the linear quadratic model. Three-dimensional dose
distributions of each treatment were accumulated on CT images of the first ICBT using DIR with commercially available
image registration software (MIM Maestro®). To compare with DIR, 3D dose distributions were fused by rigid registration
based on bony structure matching. To evaluate the accuracy of DIR, the Dice similarity coefficient (DSC) was measured
between deformed contours and initial contours.
Results: The cumulative dose distributions were successfully illustrated on the CT images using DIR. Mean DSCs of the
HR-CTV, rectum, and bladder were 0.46, 0.62 and 0.69, respectively, with rigid registration; and 0.78, 0.76, and 0.87,
respectively, with DIR (p <0.05). The mean DSCs derived from our DIR procedure were comparable to those of previous
reports describing the quality of DIR algorithms in the pelvic region. DVH parameters derived from the 2 methods
showed no significant difference.
Conclusions: Our results suggest that DIR-based dose accumulation may be acceptable for assessing cumulative dose
distributions to assess doses to the tumor and organs at risk in combined radiotherapy for cervical cancer under
pre-imaging preparations.
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The combination of external beam radiotherapy (EBRT)
and intracavitary brachytherapy (ICBT) is the standard
treatment for cervical cancer [1]. In conventional ICBT,
two orthogonal X-rays are taken and “point A” is used as
the reference point for dose prescription. “Rectal and blad-
der points” have also been used as reference points for the
assessment of rectal and bladder doses, according to
Report 38 of the International Commission on Radiation
Units and Measurements [2]. However, these points are
hypothetical, and do not always represent the actual
tumor volume or the exact locations of the highest
doses in the rectum and bladder [3,4]. Recently, three-
dimensional (3D) image modalities, such as computed
tomography (CT) and magnetic resonance imaging
(MRI), have become available for use in planning ICBT
treatment. Treatment planning based on 3D images al-
lows for assessment of 3D dose distributions and dose-
volume evaluation. The Group Européen de Curiethéra-
pie-European Society for Radiotherapy and Oncology
(GEC-ESTRO) working group for gynecologic brachy-
therapy has provided recommendations for 3D image-
based treatment planning in cervical cancer brachytherapy
[5-7]. Several studies have demonstrated that 3D dose-
volume parameters of the target volume and organs at risk
(OARs) are useful for predicting treatment response and
toxicity development [8-12].
For assessment of cumulative dose-volume relation-
ships for the target volumes and OARs in the combined
radiotherapy, the GYN GEC-ESTRO working group
suggests several parameters, including D90 of HR-CTV,
and D2cc of the rectum and bladder. These 3D dose-
volume histogram (DVH) parameters are calculated by
simply adding DVH parameters for the target volume
and OARs in EBRT for each ICBT session. However,
simple addition of DVH parameters is based on the as-
sumption that the location of the region of interest is
identical in each therapy. If the high dose area is not
consistent in each therapy, simple addition of DVH pa-
rameters does not reflect the absolute dose-volume rela-
tionship. Under such circumstances, it is necessary to
illustrate cumulative dose distributions and calculate
DVH in order to estimate the dose-volume relationship.
However, assessing cumulative dose distributions with a
conventional treatment planning system is difficult due to
the following reasons. First, as EBRT and ICBT have differ-
ent dose profiles and fractionations, it is generally difficult
to calculate DVH [13]. Second, organ motions of the
uterus, bladder, and rectum, and changes in target volume
during treatment, are significant during cervical cancer
treatment [14]; therefore dose accumulation with conven-
tional rigid registration is inaccurate and unreliable.
Recently, a few studies have demonstrated the efficacy of
DIR for evaluating cumulative dose distributions and DVHsin combined radiotherapy for various tumors [15-17].
Therefore, we aimed to conduct a pilot study to evaluate
the feasibility of DIR for assessment of cumulative dose
distributions and DVHs of combined radiotherapy for cer-




Data were collected from five consecutive patients with
locally advanced cervical cancer, who were treated with
EBRT and high-dose rate (HDR)-ICBT in our institution
between August and October 2013. All the data collec-
tions were performed after the approval of institutional
review board and acquiring written informed consent
from patients.
Treatment
EBRT was delivered to the whole pelvis with a total dose
of 45 Gy in 25 fractions using the four-field box tech-
nique with 10-MV X-ray. The clinical target volume
(CTV) of EBRT consisted of the cervical tumor, whole
uterus, bilateral parametria, at least the upper half of
the vagina, and pelvic lymph nodes (including the com-
mon, external, and internal iliac, and presacral lymph
nodes). The planned target volume (PTV) of EBRT in-
cluded the CTV plus a ≥10-mm safety margin.
High-dose-rate (HDR) ICBT was performed weekly for
four consecutive weeks using 192Ir sources. A combination
of tandem and ovoid applicators was used. CT-based 3D
image guided brachytherapy was performed for every
session of ICBT. A series of transverse CT images with
1 mm slice thickness were obtained with the applicators
in place. The high risk CTV (HR-CTV), rectum, and blad-
der were delineated according to GEC-ESTRO recom-
mendations [6]. For precise delineation, references were
always made to the MRI at diagnosis and those obtained
within a week prior to the first brachytherapy session. The
minimum dose delivered to 90% of the most irradiated
volume of HR-CTV (HR-CTV D90) and the minimum
doses delivered to 2 cm3 (D2cc) of the most irradiated vol-
umes of the rectum and the bladder were calculated and
recorded. At least 6 Gy was prescribed to HR-CTV D90
in each ICBT session. Dose constraint was 75 GyEQD2 in
D2cc of the rectum. Dose prescription and target coverage
were modified based on dose constraints for OARs.
Pre-imaging preparations for deformable image registration
Pre-imaging preparations were carefully performed before
every ICBT session, as large variation in organ position and
volume may produce fusion uncertainties and affect the
quality of DIR [18,19]. Patients were required to collect
urine one hour before undergoing CT imaging for EBRT
treatment planning. Bladder volume was confirmed by this
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with this volume of normal saline to stabilize its size and
position. The original angle and length of the longitudinal
axis of the uterus were also confirmed by treatment plan-
ning CT for EBRT. In all ICBT sessions, the angle of
uterus was kept constant by adjusting the inserting angle
of tandem applicator. Patients were required to defecate
before any treatment. Distension of the rectum was
confirmed by treatment planning CT for EBRT and
brachytherapy. If gas was observed in the rectum at ICBT,
gas drainage was performed to reduce rectal distention.
CT was retaken if gas drainage was performed.
Dose accumulation
In all cases, image registration was performed using
MIM maestro ver.6.2 (MIM Software Inc., Cleveland,
OH, USA). Doses of radiotherapy were converted into
biologically equivalent doses in 2 Gy daily fractions
(GyEQD2) using the linear quadratic model with α/β =
10 Gy for tumor tissues, and α/β = 3 Gy for normal tis-
sues [20]. At first, CT image data sets of EBRT were ri-
gidly fused by matching bony structures on CT images
of the first ICBT. Next, CT image data sets of the sec-
ond, third, and fourth ICBT sessions were rigidly fused,
referring to the applicator position in the CT images of
the first ICBT. Finally, DIR was performed to accumu-
late doses of the second, third, and fourth ICBT on the
first ICBT dose (Figure 1). Results of the DIR were care-
fully reviewed using the function of MIM maestro (Reg
Review) and modified by another function (Reg Refine).
Cumulative dose-volume evaluations
Cumulative DVHs of the HR-CTV, rectum, and bladder
were calculated based on accumulated dose distribu-
tions. DIR-based DVH parameters such as HR-CTV
D90, D2cc of the rectum and bladder were derived from
cumulative DVHs.
HR-CTV D90 and D2cc of the rectum and bladder
were also calculated using conventional simple addition
of DVH parameters. In this method DVH parameters
were calculated by adding the components of EBRT and
ICBT sessions.
Quantitative evaluation of DIR performance
Although no established method exists for estimating the
quality of DIR, the Dice similarity coefficient (DSC) is com-
monly used to evaluate the accuracy of DIR [18,21,22],
DSC was calculated by the following formula [23]:
DSC ¼ 2 VDIR∩V initialð Þ
VDIR þ V initial
In this formula, VDIR represents the volume of de-
formed contour after DIR, and Vinitial represents thevolume of contours manually delineated on the CT
image of the first ICBT session. The DSC is used to
evaluate the spatial overlap accuracy of automated seg-
mentation of images. Values for DSC range from 0 to 1,
with higher values indicating larger volumes of overlap
between two images. DSC is also calculated to estimate
overlap of the contours in case of rigid fusion.
Statistical analysis
DIR-based cumulative DVH parameters and simple DVH
parameter addition were compared using the paired t-test.
All statistical analyses were performed using IBM SPSS
Statistics for Windows, Version 21.0 (SPSS Inc., Armonk,
NY, USA). p < 0.05 was considered statistically significant.
Results
Patient characteristics
Among the 5 patients included in the study, 3 had Stage
IIB disease and 2 had Stage IIIB disease. The mean
transverse tumor diameter was 5.2 cm at diagnosis and
3.8 cm at the initiation of ICBT.
Performance of DIR
Cumulative dose distributions, consisting of EBRT and
four sessions of ICBT, were successfully illustrated using
DIR (Figure 2). Inspection by 3 radiation oncologists
(TA, TT, SK) revealed that dose distributions were illus-
trated without any irregular dose warp or irresponsible
isodose lines. A high dose area (>200 GyEQD2) was ob-
served around the center of the tumor and steep dose
decline was observed toward the peripheral area of the
tumor. HR-CTV was covered with 70–80 GyEQD2. The
parametria were covered with 50–60 GyEQD2. External
iliac, internal iliac, and obturator lymph nodes were cov-
ered with 40–50 GyEQD2 depending on the distance from
the uterus. The doses to the rectum were approximately
60–70 GyEQD2.
The mean DSCs for the HR-CTV, rectum, and bladder
were 0.46, 0.62, and 0.69, respectively, with rigid fusion,
and 0.78, 0.76, and 0.87, respectively, with DIR. Volu-
metric parameters related to our DIR procedure and
DSCs are shown in Tables 1, 2 and 3. The difference in
DSCs between the two methods was statistically signifi-
cant, suggesting the improved spatial overlap accuracy of
automated image segmentation with DIR.
DVH Parameters
The mean HR-CTV D90 and D2cc of the rectum and
bladder were 81.4 GyEQD2, 65.7 GyEQD2, and 82.8 GyEQD2,
respectively, with DIR; and 83.1 GyEQD2, 67.2 GyEQD2, and
86.6 GyEQD2, respectively, with conventional simple DVH
parameter addition. There was no statistically significant
difference in the dosimetric parameters between the two
calculation methods (Table 4). DVH parameters calculated
Figure 2 Cumulative dose distribution. A large dose gradient was observed in the irradiated field. There is an area with a very high dose at
the center of the tumor. HR-CTV was covered by a 70–80 GyEQD2 isodose line. Pelvic lymph node areas were covered by 40–50 GyEQD2 isodose
lines, depending on their distances from the central axis of the uterus.
Figure 1 The flow chart of dose accumulation. Doses of radiotherapy were converted to biologically equivalent doses in 2 Gy per fraction using
the linear quadratic model with α/β = 10 Gy for tumor tissues and α/β = 3 Gy for normal tissues. First, dose and image of EBRT were rigidly fused on
the CT image of the first ICBT. Then, using DIR, doses and images of the second, third, and fourth ICBT were accumulated on those of the first ICBT.
Abe et al. Radiation Oncology  (2014) 9:293 Page 4 of 8
Table 1 Volume of the original contour and deformed contour and the results of dice similarity coefficient (HR-CTV)
Original contour (cm3) Deformed contour (cm3) Original contour ⋂
deformed contour (cm3)
DSC by DIR DSC by rigid fusion
Case1 DIR1 25.4 29.9 25.4 0.79 0.70
DIR2 - 20.5 16.4 0.71 0.49
DIR3 - 20.0 16.6 0.73 0.57
Mean 0.75 0.59
Case2 DIR1 17.8 20.6 15.3 0.80 0.35
DIR2 18.0 13.4 0.75 0.69
DIR3 18.1 13.4 0.75 0.14
Mean 0.76 0.39
Case3 DIR1 40.0 48.7 36.5 0.82 0.25
DIR2 32.8 26.8 0.73 0.46
DIR3 33.7 27.7 0.75 0.30
Mean 0.77 0.34
Case4 DIR1 18.1 21.4 16.5 0.83 0.66
DIR2 - 13.1 10.9 0.70 0.48
DIR3 - 17.6 12.5 0.70 0.42
Mean 0.74 0.52
Case5 DIR1 27.5 24.0 20.8 0.85 0.47
DIR2 - 27.5 21.8 0.83 0.53
DIR3 - 24.8 21.7 0.88 0.43
Mean 0.86 0.48
Total Mean ± SD 0.78 ± 0.06 0.46 ± 0.16 p <0.05
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ventional method, when the anatomical locations of the
uterus, rectum, and bladder were adequately matched.
Discussion
Assessing cumulative dose distributions in combined
therapy with EBRT and ICBT for cervical cancer has
been challenging due to the difficulty in combining dif-
ferent types of fractionated radiation therapy, organ mo-
tion uncertainty, and tumor volume regression during
treatment. Dose distributions provided by the DIR ap-
peared to represent the characteristic dose profiles of
combined radiotherapy for cervical cancer. The cervical
tumor was covered with an adequately high dose, while
the surrounding normal tissues including the rectum
and bladder received minimum doses.
When evaluating DIR-based cumulative dose distribu-
tions and DVHs of the tumor and OARs, the accuracy
of DIR is of the most importance. Although there are
many uncertainties related to brachytherapy for cervical
cancer [24], the accuracy of DIR can be influenced sig-
nificantly by large inter-fractional variation in the organ
volume and position [18,19]. In this study, therefore,
pre-imaging preparations for the bladder, rectum, and
uterus were performed so as to minimize such variation.In spite of preparations, in some cases, there were still
variations in volume, shape and position of OARs which
require some adjustment by manual procedure. This
adjustment may result in variability in DIR results. With
these methods, the mean DSCs for the HR-CTV, rectum,
and bladder were 0.78, 0.72, and 0.81, respectively,
which were significantly higher than those derived from
the cumulative images by rigid fusion based on bony
structure matching (Tables 1, 2 and 3). Although DSC is
limited in that it does not include information of the de-
formation amount inside the overlapped contours, these
data suggest that improved spatial overlap accuracy was
obtained with the DIR method. There has been no defin-
ite consensus regarding the optimum DSC range. Kirby
et al. reported that the mean DSC of the rectum was
0.85 in their study comparing 11 DIR algorithms using
kilovoltage CT images of phantom [22]. Thörnqvis et al.
reported that the mean DSCs of the bladder and rectum
were 0.89 and 0.78, respectively, using one DIR algo-
rithm, and 0.81 and 0.71, respectively, using another
DIR algorithm [18].
Other factors which may affect the accuracy of DIR-
based dose-volume evaluation are voxel size and energy
conservation [25,26]. If voxel sizes of the two CT images
are different, they will be normalized to the larger one
Table 2 Volumes of the original and deformed contours and dice similarity coefficients (rectum)
Original contour (cm3) Deformed contour (cm3) Original contour ⋂
deformed contour (cm3)
DSC by DIR DSC by rigid fusion
Case1 DIR1 47.8 40.9 32.4 0.73 0.72
DIR2 - 26.9 24.6 0.74 0.66
DIR3 - 50.2 33.3 0.68 0.62
Mean 0.72 0.66
Case2 DIR1 46.6 54.1 42.5 0.85 0.74
DIR2 - 55.3 42.4 0.80 0.73
DIR3 - 48.1 40.7 0.75 0.67
Mean 0.71
Case3 DIR1 46.7 53.7 32.5 0.72 0.60
DIR2 - 47.0 29.6 0.71 0.70
DIR3 - 79.3 39.5 0.62 0.57
Mean 0.68 0.62
Case4 DIR1 95.4 59.9 56.7 0.76 0.52
DIR2 - 77.6 68.5 0.71 0.51
DIR3 - 75.7 69.0 0.84 0.41
Mean 0.77 0.48
Case5 DIR1 51.0 51.7 40.1 0.76 0.73
DIR2 - 36.9 31.4 0.74 0.50
DIR3 - 38.4 33.4 0.80 0.62
Mean 0.77 0.61
Total Mean ± SD 0.76 ± 0.05 0.62 ±0.10 p <0.05
Abe et al. Radiation Oncology  (2014) 9:293 Page 6 of 8during DIR process, and this process may cause some er-
rors in cumulative dose-volume assessment. In this study,
however, CT images were acquired with the same setting
of field of view and the same slice thickness so as to gener-
ate same voxel size. Regarding energy conservation, the
energy of radiation to one voxel may not be conserved
during DIR, especially in some situation where more than
one voxels which have different density are deformed to a
single voxel. This may also cause some errors in DIR-
based dose-volume assessment. We could not measure
the energy loss with commercially available DIR software.
This is another limitation of our study.
In this study, the values of the DIR-based DVH param-
eters were comparable to those derived from the con-
ventional simple DVH parameter addition (Table 4).
However, these results have to be carefully interpreted.
According to the GEC-ESTRO recommendations, the
DVH parameters for the target volumes and OARs in
EBRT and each ICBT session are simply added for estimat-
ing cumulative DVH parameters. In this method, however,
it has to be assumed that the location of the region of
interest is identical each time [5-7]. Therefore, the cumu-
lative DVH parameters derived from this method could be
overestimated. However, there have been several reports
that demonstrated positive correlation between cumulativeDVH parameters derived from the simple DVH parameter
addition and clinical outcomes [8-12]. It is also necessary to
evaluate the correlation between DIR-based cumulative
DVH parameters and clinical outcomes.
Theoretically, D2cc for OARs is an overestimation for
simple DVH parameter addition, while D90 for HR-CTV
is an underestimation. In our study, however, D2cc for
the rectum and bladder with DIR-based DVH accumula-
tion was higher than those with simple DVH parameter
addition in one case, respectively. D90 for the HR-CTV
with DIR-based DVH accumulation was lower in four
cases (Table 4). Four-field box technique was used in
EBRT. Inhomogeneity of EBRT doses to the uterus, rec-
tum and bladder was within ±2% with a mean dose in a
volume of interest. Therefore, inhomogeneity of dose
distributions in EBRT did not greatly affect the results.
One possible reason for the above results may be fusion
uncertainties in DIR. In our study, we fused images and
produced cumulative dose distributions for the fourth,
third and second sessions of ICBT onto those of the first
ICBT using DIR. During fractionated brachytherapy,
most cases showed rapid diminishment of the tumors.
The position and volume of the rectum and bladder also
varied greatly in Case 4 despite our attempts with pre-
imaging preparations. In addition, change in the volume
Table 3 Volumes of the original and deformed contours
















Case1 DIR1 191.2 237.9 178.2 0.86 0.83
DIR2 - 138.1 132.0 0.85 0.84
DIR3 - 276.4 177.7 0.88 0.82
Mean 0.86 0.83
Case2 DIR1 463.7 392.4 365.2 0.89 0.53
DIR2 - 434.6 121.0 0.92 0.54
DIR3 - 370.3 350.6 0.90 0.50
Mean 0.86 0.52
Case3 DIR1 231.7 411.3 223.6 0.89 0.79
DIR2 - 540.3 386.0 0.59 0.48
DIR3 - 213.9 229.4 0.93 0.82
Mean 0.80 0.70
Case4 DIR1 337.7 204.5 196.0 0.90 0.57
DIR2 - 184.7 171.5 0.91 0.60
DIR3 - 313.5 302.1 0.93 0.72
Mean 0.91 0.63
Case5 DIR1 155.9 143.0 134.2 0.89 0.77
DIR2 - 156.2 141.1 0.91 0.83













HR-CTV D90 Case 1 76.4 79.0
Case 2 84.3 82.9
Case 3 79.4 82.5
Case 4 82.1 85.6
Case 5 84.9 85.5
Mean ± SD 81.4 ± 3.5 83.1 ± 2.7 p = 0.424
Rectum D2cc Case 1 67.8 72.2
Case 2 58.0 58.2
Case 3 57.9 62.1
Case 4 74.9 74.1
Case 5 69.7 69.4
Mean ± SD 65.4± 8.3 67.2 ± 6.8 p = 0.719
Bladder D2cc Case 1 65.9 74.2
Case 2 85.2 91.4
Case 3 80.2 84.7
Case 4 104.2 102.9
Case 5 78.4 79.7
Mean ± SD 83.6 ± 11.7 86.6 ± 11.1 p = 0.687
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ation. These positional and volumetric changes may have
influenced the accuracy of image fusion in DIR. Conse-
quently, the fusion uncertainty may have resulted in the
lower D90 of HR-CTV in Cases 1, 3, 4, and 5, and the
higher D2cc of the rectum and bladder in Case 4. These
results suggest that DIR is limited in its capacity to
evaluate cumulative DVH parameters for the HR-CTV,
rectum, and the bladder. However, the differences in
D90 for HR-CTV and D2cc for the rectum and bladder
did not differ significantly between the two methods
(Table 4), and dose distributions were illustrated fairly
reasonably. Therefore, we surmise that assessment of the
cumulative dose-volume relationships using DIR may
provide beneficial information on radiotherapy for cer-
vical cancer, despite its limitations. For example, when a
midline block is inserted into the whole pelvic EBRT, it
is difficult to estimate the cumulative dose-volume relation-
ship for the target volumes and OARs by simple addition of
DVH parameters. In this case, DIR may be the only way to
illustrate cumulative dose distributions and calculate cumu-
lative DVH parameters. Furthermore, DIR may also enableto estimate the dose contributions of brachytherapy to the
parametrium or pelvic lymph node. Therefore, analysis of
cumulative dose-volume relationships using DIR may pro-
vide more accurate information if intensity modulated
radiotherapy for cervical cancer is performed.Conclusions
In conclusion, though there are some limitations in ac-
curacy of DIR, DIR-based dose accumulation may be
useful method for assessing cumulative dose-volume re-
lationship in the combined radiotherapy for cervical can-
cer, especially when assessing dose of the combination of
midline block EBRT and brachytherapy.
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